The FDA has approved two cell and gene therapies for sickle cell disease, marking a significant development for the largest population condition to date. However, the high treatment costs, … Read More
NEWDIGS welcomes Dr. Sharon Phares as new Associate Director for Research
NEWDIGS at Tufts Medical Center is excited to announce that Sharon Phares, PhD, MPH, has joined the team as our Associate Director for Research, Center for Biomedical System Design (CBSD), Tufts Medicine earlier this … Read More
Ask PAM: “How many?”
Individual Indication Workbook in actionHow many treatment-eligible people are in my population?The Pipeline Analysis and Modeling (PAM) in the NEWDIGS Paying for Cures Toolkit maintaints a unique, detailed, indication-by-indication analysis … Read More
Analyzing 340B and ASP interactions: Do Federal program rules disincentivize the use of VBCs, despite Medicaid Best Price reform?
This paper describes the interactions among Medicaid Best Price rebate calculations and those for 340B Ceiling Prices and Average Sales Prices which can create disincentives for providers and therapy developers … Read More
Orphan cell and gene therapies more likely to reach approval than larger drug pipeline: study
Our new report shows that cell and gene therapies for orphan diseases and hematological cancers are two to 3.5 times more likely to be successful than other types of treatments … Read More
Are Cell and Gene Therapy programs a better bet?
Compared to traditional drug development programs, do durable cell and gene therapy (CGT) programs experience higher or lower clinical success rates? Estimating the Probability of Technical and Regulatory Success (PTRS) … Read More
New Analysis by Tufts’ NEWDIGS Shows that Durable Cell and Gene Therapies Have Substantially Higher Clinical Success Rates than Other Treatments
Findings to be shared during ARM’s annual Cell & Gene Meeting on the Mesa Carlsbad, CA – The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization championing the benefits … Read More
Extending the vision of adaptive point-of-care platform trials to improve targeted use of drug therapy regimens: An agile approach in the learning healthcare system toolkit
Publication in Contemporary Clinical Trials To improve drug regimen use, we propose an adaptive point-of-care (APoC) platform trial for robust real-world evidence (RWE) production, addressing uncertainties post-market. Using rheumatoid arthritis … Read More
Innovating methods for planning, producing, and using real-world evidence
Real-world data (RWD) are a critical element of the evidence needed to help reach this goal, potentially informing a new drug’s development or providing insight for its use after it … Read More
Payer and developer perspectives on alternative payment models
Expert Review of Pharmacoeconomics & Outcomes Research, Volume 24, 2024 – Issue 2Moradian, R., Meshesha, T., Trusheim, M., & Barlow, J. F. The paper reports the results of a survey … Read More